-+ 0.00%
-+ 0.00%
-+ 0.00%
Siemens Healthineers and Novo Join Forces to Advance Care for People Living with MASLD and MASH
Share
Listen to the news

Tarrytown, New York, USA, Sept. 21, 2026 (GLOBE NEWSWIRE) --

Siemens Healthineers and Novo have announced a collaboration focused on advancing care for people living with metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH). The companies are engaged in several projects to strengthen disease awareness, support earlier assessment of the disease, and help expand patient access to non-invasive blood testing.

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending